# A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

> **NCT01656642** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 67 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Cobimetinib
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT01656642
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-13
- **Primary completion:** 2020-03-25
- **Final completion:** 2020-03-25
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2020-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01656642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01656642, "A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01656642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*